Cellectis (NASDAQ:CLLS) Stock Price Crosses Below Fifty Day Moving Average – Time to Sell?

Cellectis S.A. (NASDAQ:CLLS) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.67 and traded as low as $3.10. Cellectis shares last traded at $3.11, with a volume of 9,983 shares.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Barclays assumed coverage on Cellectis in a report on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price for the company. Citizens Jmp reaffirmed a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a report on Tuesday, April 14th. Finally, Jefferies Financial Group assumed coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Cellectis Price Performance

The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. The stock has a market cap of $312.06 million, a price-to-earnings ratio of -4.64 and a beta of 2.86. The stock has a fifty day moving average of $3.67 and a 200 day moving average of $3.94.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. B Group Inc. raised its position in Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after acquiring an additional 25,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Cellectis during the fourth quarter valued at approximately $15,385,000. Citadel Advisors LLC purchased a new position in Cellectis during the third quarter valued at approximately $633,000. Finally, Marshall Wace LLP raised its position in Cellectis by 1,610.3% during the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 168,038 shares in the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.